Jan. 30 at 1:24 PM
$CLDI don’t forget The CEO did this at his last company too: @Slinde1
Biotech penny-stock scams usually focus on selling a medical story, not building a product. They promote vague “breakthroughs” with heavy buzzwords, selective preclinical data, and frequent press releases implying FDA progress or partnerships—without independent validation—drawing in retail investors and inflating the stock through hype rather than results. Scientific details are thin, timelines shift constantly, and real clinical advancement never seems to arrive.
The real business is dilution. After price spikes, the company issues shares via offerings or toxic convertibles, directing cash to salaries, consultants, and insider-linked entities instead of meaningful R&D. When momentum fades, delays are blamed on regulators, strategic pivots are announced, reverse splits reset the price, and shareholders are steadily wiped out while insiders profit and often resurface under a new ticker.
